CLINICAL TRIALS PROFILE FOR ETHINYL ESTRADIOL; NORGESTREL
✉ Email this page to a colleague
All Clinical Trials for ethinyl estradiol; norgestrel
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00033358 ↗ | Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2002-02-01 | Randomized phase II trial to compare two different hormone therapy regimens in preventing endometrial cancer in women who have a genetic risk for hereditary nonpolyposis colon cancer. Hormone therapy may prevent the development of endometrial cancer in women with a genetic risk for hereditary nonpolyposis colon cancer. It is not yet known which hormone therapy regimen is more effective in preventing endometrial cancer. |
| NCT00254865 ↗ | A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | 2002-08-01 | The objective of this study is to compare the levels of the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers administered ORTHO EVRA® (a transdermal contraceptive patch) and CILEST® (an oral contraceptive). The open-label treatment phase of the study consists of two 28-day cycles of one treatment, a washout period of 28 days, and crossover to two 28-day cycles of the other treatment. |
| NCT00258063 ↗ | A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive) | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | 2004-05-01 | The objective of this study is to estimate exposure to the hormones norelgestromin, norgestrel, and ethinyl estradiol in healthy female volunteers across multiple commercial lots of EVRA® (a transdermal contraceptive patch manufactured by LOHMANN Therapie-Systeme), to compare these data to exposure data from one clinical lot, and to compare these data to exposure data from a commercially available oral contraceptive. |
| NCT00258076 ↗ | A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch) | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | 2004-04-01 | The objective of this study is to estimate the exposure to the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers across multiple commercial lots of ORTHO EVRA® (a transdermal contraceptive patch) and to compare these data to historical hormonal exposure data from one ORTHO EVRA® clinical development lot. |
| NCT02792517 ↗ | Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females | Completed | Amgen | Phase 1 | 2016-02-12 | A pharmacokinetic drug interaction study of erenumab and an oral contraceptive containing progestin and estrogen. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ethinyl estradiol; norgestrel
Condition Name
Clinical Trial Locations for ethinyl estradiol; norgestrel
Trials by Country
Clinical Trial Progress for ethinyl estradiol; norgestrel
Clinical Trial Phase
Clinical Trial Sponsors for ethinyl estradiol; norgestrel
Sponsor Name
